Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1888 - Clinical impact of 18F-FDG-PET/CT (PET) in patients (P) with oligometastatic disease (OMD) at a skin and gastrointestinal tumour section.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Gastrointestinal Cancers

Presenters

Juan Jose Garcia-Mosquera

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

J.J. Garcia-Mosquera1, L. Layos Romero1, C. Buges1, S. España Fernandez1, S. Chen2, J.M. Velarde2, E. Felip1, C. Erasun Lecuona1, L. Angelats2, M. Cucurull Salamero1, J.L. Manzano2

Author affiliations

  • 1 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 2 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1888

Background

Is important to avoid aggressive treatments in P with OMD with undetected metastasis. Previous data demonstrated that PET can have a significant clinical impact, especially in colorectal cancer.

Methods

Retrospectively, we review the history of P studied with PET at our unit, from October 2013 to December 2017. We included only P with OMD with a PET done to complete disease extension study in addition to conventional imaging and previously to undergo a potential curative management. Baseline data (age, sex, primary and stage), disease extension and initial strategy before PET were collected. After PET, disease extension, definitive strategy and overall survival (OS) was determined.

Results

Overall, 93 P met the inclusion criteria: 72 (77%) colorectal (CRC), 13 (14%) melanoma, 4 (4%) biliary tract, 2 (2%) oesophageal and 2 (2%) other primaries. The mean age was 64 years (range: 24-83) and 58 (62%) P were male. At debut, 64 (79%) P were non-metastatic, and PET was done at the recurrence. After PET, 47 (51%) P were restaged: 35 (38%) were upstaged and 12 (13%) were downstaged. Final strategy was changed in 43 (46%) P, leading to a non-radical plan in 32 (34%) P. On the radical plan group there was 2 (2.2%) p with no malignant disease after surgery (pulmonary tuberculosis and aspergillosis). Median OS after PET in CRC cohort with changed strategy was significantly lower (28m, CI 95% 23-32) versus cohort without changes (47m, CI 95% 29-65); p-value 0.03.

Conclusions

After PET approximately half of P were restaged, consequently avoiding aggressive strategies in one-third of P. PET seems to be effective in selecting P with poor overall survival outcomes that need a palliative rather than a radical management. PET has relevant advantages compared with conventional imaging in the selection of P with OMD disease who may be eligible for surgery or local techniques.

Clinical trial identification

Legal entity responsible for the study

Catalan Institute of Oncology (ICO Badalona).

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.